Skip to main content
BRNS
NASDAQ Life Sciences

Barinthus Biotherapeutics Reports Significantly Reduced Q1 Loss and Extended Cash Runway Amidst Merger Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.63
Mkt Cap
$24.505M
52W Low
$0.512
52W High
$2.92
52W Position info
23% above low
Off High info
78% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

BRNS sits 23% above its 52-week low of $0.512 on light trading volume (0.3× avg).

Summary

Barinthus Biotherapeutics reported a significantly reduced net loss and cash burn in Q1 2026, extending its cash runway for over 12 months, while providing detailed financial context for its pending merger with Clywedog Therapeutics.


Key Events · Earnings and Guidance · BRNS

  • Net Loss Significantly Reduced

    The company reported a net loss of $5.5 million for Q1 2026, a substantial improvement from a $19.7 million net loss in Q1 2025, driven by strategic cost reductions.

  • Operating Cash Burn Decreases

    Net cash used in operating activities decreased to $3.4 million in Q1 2026, down from $14.9 million in Q1 2025, reflecting improved operational efficiency.

  • Extended Cash Runway Confirmed

    Barinthus Biotherapeutics confirmed that its cash, cash equivalents, and restricted cash of $67.2 million as of March 31, 2026, are sufficient to fund operations for at least the next 12 months.

  • Merger with Clywedog Progressing

    The filing reiterates the ongoing all-stock merger with Clywedog Therapeutics, expected to close in mid-2026, with a potential self-tender offer of up to $27.0 million for the combined company's shares.


Analysis · BRNS · Life Sciences

This quarterly report details a substantial improvement in Barinthus Biotherapeutics' financial performance for Q1 2026, with net loss significantly reduced to $5.5 million from $19.7 million in Q1 2025. Operating cash burn also decreased dramatically to $3.4 million from $14.9 million in the prior year period. These improvements are attributed to strategic reprioritization of programs and cost reductions, including the closure of the UK laboratory. The company confirms sufficient cash, cash equivalents, and restricted cash of $67.2 million to fund operations for at least the next 12 months, a critical 'going concern' statement for a clinical-stage biotech. The filing also provides detailed financial context for the ongoing all-stock merger with Clywedog Therapeutics, which is expected to close in mid-2026 and may include a self-tender offer of up to $27.0 million for the combined entity's shares. This detailed financial update, following a recent Nasdaq delisting notice, provides crucial clarity on the company's financial health and the path forward with the merger.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BRNS was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.5M. The 52-week trading range was $0.51 to $2.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BRNS - Latest Insights

BRNS
Sep 01, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.765
Real-time Price: $0.800 info
Change: +$0.035 (+5%) info
Market Cap: $30.232M info
BRNS
Aug 25, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.603
Real-time Price: $0.800 info
Change: +$0.197 (+33%) info
Market Cap: $30.232M info
BRNS
Aug 06, 2026, 8:49 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5705
Real-time Price: $0.800 info
Change: +$0.2295 (+40%) info
Market Cap: $30.232M info
BRNS
Aug 06, 2026, 8:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.800 info
Change: +$0.210 (+36%) info
Market Cap: $30.232M info
BRNS
Jul 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6201
Real-time Price: $0.800 info
Change: +$0.1799 (+29%) info
Market Cap: $30.232M info